Product Highlight - Xarelto
25 Jun 2020
The First & Only NOAC Approved for CAD/PAD1*
Xarelto, co-administered with ASA, is indicated for the prevention of atherothrombotic events in adult patients with CAD or symptomatic PAD at high risk of ischaemic events.2
In the COMPASS trial, Xarelto 2.5 mg bid + aspirin vs aspirin alone:
• -24% primary outcome: CV death, stroke or MI (p<0.001)3
• -23% all-cause mortality in CAD patients (p=0.0012)4
• -46% MALE and major amputations in PAD patients (p=0.0037)5
• No significant increase in the risk of most serious bleeding3
• Recommended by the 2019 ESC6 and ESVM7 Guidelines
ASA: acetylsalicylic acid; CAD: coronary artery disease; CV: cardiovascular; ESC: European Society of Cardiology; ESVM: European Society for Vascular Medicine; MALE: major adverse limb events; MI: myocardial infarction; NOAC: non-vitamin K oral anticoagulant; PAD: peripheral artery disease.
*As of Apr 1, 2020
References:
1. U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) [news release]. Titusville, NJ; October 11, 2018: Janssen Pharmaceuticals website. https://www.janssen.com/us-fda-approves-xareltor-rivaroxaban-reduce-risk-major-cardiovascular-events-patients-chronic. Accessed Apr 1, 2020.
2. Xarelto Hong Kong prescribing information.
3. Eikelboom JW, et al. N Engl J Med 2017;377:1319–1330.
4. Connolly SJ, et al. Lancet 2017; doi: 10.1016/S0140–6736(17)32458–3.
5. Anand SS, et al. J Am Coll Cardiol 2019;73:3271–80.
6. Neumann FJ, et al. European Heart Journal (2019) 00, 1-71. doi:10.1093/eurheartj/ehz425.
7. Frank U, et al. Vasa (2019), 48 (Supplement 102).
BAYER HEALTHCARE LIMITED
14th Floor, Oxford House, Taikoo Place,
979 King’s Road, Quarry Bay, Hong Kong
Tel: (+852) 8100 2755
Fax: (+852) 3526 4755
Xarelto, co-administered with ASA, is indicated for the prevention of atherothrombotic events in adult patients with CAD or symptomatic PAD at high risk of ischaemic events.2
In the COMPASS trial, Xarelto 2.5 mg bid + aspirin vs aspirin alone:
• -24% primary outcome: CV death, stroke or MI (p<0.001)3
• -23% all-cause mortality in CAD patients (p=0.0012)4
• -46% MALE and major amputations in PAD patients (p=0.0037)5
• No significant increase in the risk of most serious bleeding3
• Recommended by the 2019 ESC6 and ESVM7 Guidelines
ASA: acetylsalicylic acid; CAD: coronary artery disease; CV: cardiovascular; ESC: European Society of Cardiology; ESVM: European Society for Vascular Medicine; MALE: major adverse limb events; MI: myocardial infarction; NOAC: non-vitamin K oral anticoagulant; PAD: peripheral artery disease.
*As of Apr 1, 2020
References:
1. U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) [news release]. Titusville, NJ; October 11, 2018: Janssen Pharmaceuticals website. https://www.janssen.com/us-fda-approves-xareltor-rivaroxaban-reduce-risk-major-cardiovascular-events-patients-chronic. Accessed Apr 1, 2020.
2. Xarelto Hong Kong prescribing information.
3. Eikelboom JW, et al. N Engl J Med 2017;377:1319–1330.
4. Connolly SJ, et al. Lancet 2017; doi: 10.1016/S0140–6736(17)32458–3.
5. Anand SS, et al. J Am Coll Cardiol 2019;73:3271–80.
6. Neumann FJ, et al. European Heart Journal (2019) 00, 1-71. doi:10.1093/eurheartj/ehz425.
7. Frank U, et al. Vasa (2019), 48 (Supplement 102).
BAYER HEALTHCARE LIMITED
14th Floor, Oxford House, Taikoo Place,
979 King’s Road, Quarry Bay, Hong Kong
Tel: (+852) 8100 2755
Fax: (+852) 3526 4755
